ImmunoPrecise Antibodies Ltd. (IPA)

Market Cap	16.53M
Revenue (ttm)	17.27M
Net Income (ttm)	-20.02M
Shares Out	33.53M
EPS (ttm)	-0.74
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	138,146
Open	0.525
Previous Close	0.530
Day's Range	0.492 - 0.548
52-Week Range	0.325 - 2.600
Beta	0.19
Analysts	Strong Buy
Price Target	5.00 (+914.2%)
Earnings Date	Mar 13, 2025

About IPA

ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and artificial intelligence through a series proprietary and patented technologies. The company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving industry challenges. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibod...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 3, 2017
• Employees: 101
• Stock Exchange: NASDAQ
• Ticker Symbol: IPA
• Website: https://www.ipatherapeutics.com

Financial Performance

In 2024, ImmunoPrecise Antibodies's revenue was 24.52 million, an increase of 18.65% compared to the previous year's 20.67 million. Losses were -27.18 million, 2.32% more than in 2023.

Financial numbers in CAD

Analyst Forecast

According to 2 analysts, the average rating for IPA stock is "Strong Buy." The 12-month stock price forecast is $5.0, which is an increase of 914.20% from the latest price.

Price Target

$5.0

(914.20% upside)

Analyst Consensus: Strong Buy